Open Access
Access granted
Subscription or Fee Access
No 1s (2012)
- Year: 2012
- Articles: 9
- URL: https://journals.eco-vector.com/2073-4034/issue/view/6739
Articles
MESTO PUNKTsIONNOY BIOPSII V DIAGNOSTIKE KhRONIChESKIKh DIFFUZNYKh ZABOLEVANIY PEChENI
Abstract
The article proves necessity for the assessment of necro-inflammation, fibrosis and steatosis in the diagnosis of chronic diffuse liver diseases and in the control of effectiveness of their treatment. The potentials and limitations for the use for this purpose of liver biopsy, and liver elastography and Fibro/ActiTest and FibroMax diagnostic panels as an alternative, are considered. It is emphasized that the use of these non-invasive methods of diagnosis of chronic diffuse liver diseases allows to evaluate the hepatic fibrosis, activity of disease and severity of steatosis without a needle biopsy.
Pharmateca. 2012;(1s):3-6
3-6
DIAGNOSTIKA I LEChENIE OSLOZhNENIY TsIRROZA PEChENI
Abstract
The article considers current recommendations for the diagnosis and treatment of complications of hepatic cirrhosis (HC), such as hepatic encephalopathy, ascites (with or without contamination of ascitic fluid), hepatorenal syndrome, bleeding from esophageal and gastric varices, and dilutional hyponatremia. It is emphasized that liver transplantation is a single effective of radical treatment of HC complications, which, unfortunately, is not always possible to perform in a timely manner. The correct choice of treatment of HC complications is a very difficult task, but its implementation will allow patients to safely waiting for a liver transplantation
Pharmateca. 2012;(1s):7-18
7-18
SKRININGOVOE OBSLEDOVANIE BOL'NYKh S KhRONIChESKIMI ZABOLEVANIYaMI PEChENI DLYa VYYaVLENIYa RANNIKh STADIY GEPATOTsELLYuLYaRNOGO RAKA
Abstract
The results of the screening for hepatocellular carcinoma (HCC) in 5960 of high-risk patients are presented. As a part of survey, patients underwent ultrasound examination and determination of α-fetoprotein (spiral computed tomography with contrast enhancement and liver biopsy, as appropriate). HCC diagnosis was verified in 69 cases; more frequently HCC was found in patients with hepatic cirrhosis - 33 (4,35%) cases.
Pharmateca. 2012;(1s):19-22
19-22
VOZMOZhNOSTI PRIMENENIYa MAGNITNOREZONANSNOY TOMOGRAFII V UTOChNENNOY DIAGNOSTIKE GEPATOTsELLYuLYaRNOGO RAKA
Abstract
The study including 25 patients with hepatocellular carcinoma has evaluated the potentials for the accurate differential diagnosis of hepatocellular carcinoma (HCC) using the hepato-specific contrast agent, a gadoxetic acid (Primovist), and diffusion-weighted magnetic resonance imaging (DWI). It was found that the combination of a number of MRI signs - diffuse heterogeneous "amplification" of focus in the arterial phase, rapid "washout" of contrast agent in the venous phase (with persistent heterogeneity of the internal structure of the focus), hyperintensity on DWI with isointensity on ICD-cards and hypointensity of focus in hepatospecific phase - allows to reliable identify such detectable focal lesion as HCC.
Pharmateca. 2012;(1s):23-25
23-25
POKAZANIYa K KhIRURGIChESKOMU LEChENIYu PRI GEPATOTsELLYuLYaRNOY KARTsINOME
Abstract
In most countries worldwide, morbidity and mortality from primary malignant liver tumors are increased; hepatocellular carcinoma (HCC) is diagnosed in more than 90% of patients. In compliance with the Milan criteria, the liver resection remains the main treatment of HCC, with a hope of satisfactory long-term results. The preservation of the liver function is important, because the frequency of concomitant liver cirrhosis in patients with HCC is 80%. In recent years, due to best surgical practice and improvement of postoperative management of patients, mortality after liver resection for HCC is less than about 9%, and 5-year survival rate is 37%. Nevertheless, the problem is especially acute for volume of liver resection, depending on the extent of tumor and the stage of concomitant hepatic cirrhosis
Pharmateca. 2012;(1s):26-29
26-29
LOKOREGIONARNYE INTERVENTsIONNORADIOLOGIChESKIE TEKhNOLOGII V LEChENII GEPATOTsELLYuLYaRNOGO RAKA
Abstract
The article discusses the variants of locoregional treatment of hepatocellular carcinoma (HCC) in case of inability to perform liver transplantation or resection. These include the technologies of local destruction (percutaneous ethanol injection, radiofrequency ablation) and intravascular methods of antitumor therapy (transarterial chemoembolization, transarterial radioembolization). With an adequate selection of patients, these treatments are effective and safe. Currently, prospects for combined use of different locoregional interventional radiological techniques and their combination with systemic anticancer therapy in HCC are under investigation.
Pharmateca. 2012;(1s):30-37
30-37
VEDENIE PATsIENTOV S KhRONIChESKIMI VIRUSNYMI GEPATITAMI I ONKOLOGIChESKOY PATOLOGIEY
Abstract
The main principles of management of patients with cancer in the presence of concomitant chronic viral hepatitis (HBV-, HCV-and HDV-infection) are considered. The problems of antiviral treatment and characteristics of anticancer therapy of these patients are discussed.
Pharmateca. 2012;(1s):38-41
38-41
SORAFENIB V LEChENII RASPROSTRANENNOGO GEPATOTsELLYuLYaRNOGO RAKA
Abstract
The article presents the results of a prospective study on effectiveness of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) in ROSC named after N.N. Blokhin and other oncological centers in Russia for the period from February 2009 to August 2012. The study included 130 patients treated with peroral sorafenib in an initial dose of 400 mg 2 times a day daily. The study confirmed the international evidence on the efficacy and safety of sorafenib in patients with advanced HCC with satisfactory liver function (Child Pugh class A). It is emphasized that a careful dynamic assessment of functional status of the liver, appropriate and timely treatment of pre-existing liver diseases and toxicity of sorafenib are the basis for an effective anti-tumor treatment of HCC.
Pharmateca. 2012;(1s):42-49
42-49
Diagnostika, stadirovanie i lechenie gepatotsellyulyarnoy kartsinomy (mezhdistsiplinarnye rekomendatsii) - Bol'nitsa obshchego profilya Veny Kampus Meditsinskogo universiteta Standartnaya operatsionnaya protsedura
Pharmateca. 2012;(1s):50-56
50-56